Outset Medical (OM) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue reached $29.8 million, up 6% year-over-year, driven by strong recurring and console revenue growth.

• Recurring revenue rose 20% year-over-year to $22.7 million, with robust utilization across the installed base.

• Gross margin expanded to 37.2% (GAAP) and 37.6% (non-GAAP), reflecting operational improvements and favorable product mix.

• Net loss narrowed to $25.8 million (GAAP) and $22.8 million (non-GAAP), both significantly improved from Q1 2024.

• Liquidity was strengthened by a $172.7 million private placement and $100 million term loan, supporting ongoing restructuring and cost optimization.

Financial highlights

• Product revenue was $21.3 million (+4% year-over-year); service and other revenue was $8.5 million (+9% year-over-year).

• Gross profit increased 35% to $11.1 million; product gross margin was 48.3%–48.4%, service gross margin was 9.2%–10.3%.

• Operating expenses declined 39% year-over-year to $27.5 million, with non-GAAP OPEX at $24.6 million.

• Net loss per share improved to $(3.66) GAAP and $(3.24) non-GAAP, compared to $(11.77) and $(8.62) in Q1 2024.

• Cash, cash equivalents, and short-term investments totaled $192–$192.3 million at quarter end.

Outlook and guidance

• Full-year 2025 revenue expected between $115 million and $125 million, with recurring revenue and installed base projected to grow ~10%.

• Gross margin for 2025 expected in the high 30% range; Q4 gross margin anticipated above 40% excluding under-absorption.

• Cash usage for 2025 projected under $50 million, less than half of 2024.

• Management expects continued operating losses in the near term as investments support anticipated growth.

• Guidance remains conservative due to execution risk and macroeconomic uncertainties.